{'fraction_non_alphanumeric': 0.03151862464183381, 'fraction_numerical': 0.0038204393505253103, 'mean_word_length': 5.429447852760736, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Comparative study of two fusion retinoic acid receptor alpha in acute promyelocytic leukemia].

OBJECTIVE
To make a comparison of biological properties between PML-RARalpha and PLZF-RARalpha fusion proteins.


METHODS
Receptor radioligand binding assay, receptor DNA binding assay and immunofluorescence methods were used.


RESULTS AND CONCLUSION
PML-RARalpha and PLZF-RARalpha had similar ligand-binding affinities. Both could bind in vitro to retinoic acid response elements (RAREs) forming homodimers and to retinoic acid X receptor. However ,they differed in the relative binding affinities to different RAREs,the behavior of forming complex with RXR and the subcellular localization. More importantly, PML-RARalpha and PLZF-RARalpha could block different regulatory pathways mediated by PML or PLZF, through heterocomplex formation with wild-type PML or PLZF. The differences between PML-RARalpha and PLZF-RARalpha may in part explain the apparent resistance of APL with t(11;17) to differentiating effect of all-trans retinoic acid (ATRA).